Supported by an educational grant from LEO Pharma
Identify updates on oral therapies for Psoriasis
Evaluate comparative efficacy of biologics for Psoriasis and Psoriatic Arthritis
Understand and Implement the AAD Psoriasis Guidelines
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
April Armstrong, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: Abbvie, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, LEO Pharma, Modernizing Medicine, Novartis AG, Ortho Dermatologics, Pfizer, Inc ., Regeneron Pharmaceuticals, Sanofi Genzyme and Science 37 . Grant/Research Support: Abbvie, Bristol-Myers Squibb, Dermira, Eli Lilly, Janssen, Kyowa Hakko Kirin, LEO Pharma, Novartis, Regeneron, Sanofi, and UCB.
Accreditation and Medical Education Support Disclosure
Susan Gallagher-Pecha and Erin Fletcher of Evolve Medical Education LLC have no real or apparent conflicts of interest to report.
Stacey Moore of Physician Resources, LLC has no real or apparent conflicts of interest to report.